Priprava i evaluacija mukoadhezivnih filmova glipizida by GANESH RAJPUT et al.
Oral sustained-release technology provides oral delivery for 24 h; however, in sub-
stances that cannot be well absorbed throughout the whole gastrointestinal tract, may be
disadvantageous (1). Extended-release dosage forms with prolonged residence times in
the stomach are highly desirable for drugs with narrow absorption windows, stability
problems in the intestinal or colonic environments, locally acting in the stomach, and
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Glipizide is mainly absorbed in the proximal areas of the
gastrointestinal tract. The purpose of this study was for-
mulation and evaluation of mucoadhesive films to pro-
long the stay of drug in its absorption area. Glipizide
was formulated in a mucoadhesive film that could be re-
tained in the stomach for prolonged intervals. Polymeric
films were designed with various compositions of hy-
droxypropyl cellulose and polyethylene glycol 400 (PEG
400). Properties of the mucoadhesive film such as tensile
strength, percentage elongation, swelling index, mois-
ture content, pH and viscosity of polymeric dispersion,
film thickness, content uniformity and mucoadhesion in
a simulated gastric environment were characterized. In
addition, percentage drug retained in stomach mucosa
was estimated using a simulated dynamic stomach sys-
tem as a function of time. Increase in hydroxypropyl cel-
lulose concentration resulted in a higher tensile strength
and elongation at break, while increase in concentration
of PEG 400 was reflected in a decrease in tensile strength
and increase of elongation at break. Glipizide/hydroxy-
propyl cellulose/PEG 400 (2.5:1:0.5) (GF5) was found to
be the optimal composition for a novel mucoadhesive
stomach formulation that showed good peelability, rela-
tively high swelling index, moderate tensile strength,
and stayed on rat stomach mucosa up to 8 h. In vivo test-
ing of the mucoadhesive films with glipizide demon-
strated a potential hypoglycemic effect.
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poor solubility in the intestine (2). Recent approaches to increasing the gastric residence
time of drug delivery systems include bioadhesive devices, swelling devices that incre-
ase their size, low density devices, floating systems, high density systems, magnetic sys-
tems, unfoldable and expandable systems, superporous, biodegradable hydrogel systems
and microparticulate systems (3).
The otherwise excellent concept of floating system suffers from the disadvantage that
it is effective only when the fluid level in the stomach is sufficiently high. However, as
the stomach empties and the tablet is at the pylorus, the buoyancy of the dosage form
may be impeded (4). This serious limitation can be overcome by coupling mucoadhesion
characteristics to the dosage form and developing mucoadhesive films. Floating and bio-
adhesive drug delivery systems have advantages such as efficient absorption and en-
hanced bioavailability of drugs owing to a high surface-to-volume ratio, a much more
intimate contact with the mucus layer, and specific targeting of drugs to the absorption
site. The various buoyant preparations include microballoons, microspheres, granules,
powders, gel, capsules, tablets, and laminated films (5, 6). Matrix tablets based on hy-
droxypropyl methylcellulose (HPMC K4M) have been developed by Li et al. (7), and mi-
croparticulate systems using natural polymers have been evaluated for stomach specific
drug delivery of glipizide (8).
Glipizide is a second-generation sulfonylurea that can acutely lower the blood glu-
cose level in humans by stimulating the release of insulin from the pancreas: it is typi-
cally prescribed to treat type II diabetes (non-insulin-dependent diabetes mellitus). Its
short biological half-life (3.4 ± 0.7 h) necessitates to be administered in 2 or 3 doses of 2.5
to 10 mg per day. Thus, the development of controlled-release dosage forms would clea-
rly be advantageous. Researchers have formulated oral controlled-release products of gli-
pizide by various techniques (9, 10). Moreover, the site of glipizide absorption is in the
stomach. Dosage forms that are retained in the stomach would increase absorption, im-
prove drug efficiency, and decrease dose requirements.
The hypothesis for this research work is that if glipizide can be delivered in a con-
trolled manner to the duodenum at a rate that does not exceed the maximum rate of its
absorption, then the oral bioavailability of glipizide could be improved. Based on this
hypothesis, the mucoadhesive films were designed in such a way that they should be re-
tained in the stomach for a prolonged period of time, thus maximizing the exposure of
the drug to its absorption site.
EXPERIMENTAL
Materials
Glipizide was obtained as a gift sample from USV Ltd. (India), hydroxypropyl me-
thylcellulose (HPMC E15) was donated by Colorcon Asia Pvt. Ltd. (India), hydroxypro-
pyl cellulose (HPC) was purchased from Innovative Chemicals (India), sodium alginate,
hydroxyethyl cellulose (HEC) were purchased from Himedia (India), D-sorbitol, glyce-
rol and polyethylene glycol 400 (PEG 400) were purchased from S. D. Fine Chemicals
(India). All other chemicals used were of analytical grade.
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Animals
Six-month-old, mixed sex, specific pathogen-free healthy Wistar rats (weighing
250–300 g), were obtained from Zydus Cadila (India) and maintained under standard la-
boratory conditions (room temperature 23 ± 2 °C, relative humidity 55 ± 5 %; 12/12 h
light/dark cycle) with free access to a commercial rodent diet and tap water.
Drug-excipient compatibility
Compatibility of glipizide and different polymers to be used for the development of
film formulations was studied using a differential scanning calorimeter (DSC 60, Shima-
dzu, Japan) at a nitrogen flow of 30 mL min–1 and heating rate of 15 °C min–1 from 35 to
300 °C. Results of glipizide-excipient compatibility study performed by DSC are shown
in Fig. 1.
Preparation of films
Mucoadhesive films were prepared by the solvent evaporation technique (11), using
glipizide, plasticizer and other film forming polymers. Glipizide was added into distil-
led water and sonication was done for 15 min to obtain an aqueous dispersion. Subse-
quently, the film forming polymer and plasticizer were added to this dispersion. This
polymeric dispersion was stirred on a magnetic stirrer (Remi Equipments Ltd., India) for
30 min, followed by sonication for 15 min and kept for 3 h to remove all the entrapped
air bubbles. Polymeric dispersion was uniformly spread onto a plastic plate of defined
area (10 cm2) and dried in vacuum oven at 50 °C for 20 h. Dried films were carefully
peeled off from the plate surface, cut into pieces of defined size (1.0 × 1.0 cm). Then,
films were sealed in sachets prepared from polyethylene laminated aluminum foil and
stored at a temperature of 30 ± 2 °C and relative humidity 60 ± 5 % until further analysis.
Composition of glipizide films prepared with various polymers and plasticizers and their
physical characteristics are reported in Table I.
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Fig. 1. Representative DSC thermogram for glipizide-excipient compatibility study.
Factorial design and the desirability function
To study all possible combinations of all factors at all levels (two factors, three lev-
els), full factorial design was constructed and conducted in a fully randomized order.
The dependent variables to be measured were tensile strength, elongation (%) and drug
released from films after 8 h (Y8, %). The composition and responses of the 32 factorial
design are shown in Tables I and II. Two independent factors, concentration of HPC (X1)
and PEG 400 (X2), were set at three different levels. High and low levels of each factor
were coded as 1 and –1, respectively, and the mean value as zero. The range of a factor
was chosen in order to adequately measure its effects on the response variables. This de-
sign was selected because it provides sufficient degrees of freedom to resolve the main
effects as well as factor interactions.
The desirability function was used for optimization of the formulation composition.
In addition, the responses had to be combined in order to produce a product of desired
characteristics. The application of the desirability function combines all the responses in
one measurement and offers the possibility to predict optimum levels for the independ-
ent variables.
The combination of responses in one desirability function requires the calculation of
individual functions. An ideal film should have moderate tensile strength, high elonga-
tion and high percentage of drug retained on the stomach mucosa. The individual desira-
bility and prediction profiles for each response were calculated using the JMP 5.1 (JMP®,
USA) statistical discovery software (12).
In this study, there were no specific requirements for tensile strength of the opti-
mum formulation. Therefore, the range of values of produced formulations was selec-
ted. As moderate tensile strength was desired, the formulation that had the value within
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Table I. Composition of the glipizide film with various polymers and plasticizers






GLF1 – D-sorbitol 1.0:0:0.5
Not removable from casting
surface
GLF2 – glycerol 1.0:0:0.5
Not removable from casting
surface
GLF3 – PEG 400 1.0:0:0.5
Not easily removable from
casting surface
GLF4 HEC PEG 400 1.0:1.0:0.5
Non homogeneous surface,
more soft, easy to peel
GLF5 Sodium alginate PEG 400 1.0:1.0:0.5 Brittle, hard to peel
GLF6 HPC PEG 400 1.0:1.0:0.5
Homogeneous surface, soft,
easy to peel
HEC – hydroxyethyl cellulose, HPC – hydroxypropyl cellulose, PEG 400 – polyethylene glycol 400
the range of 7.0–10.0 had a desirability of 1, while the formulations that had values out
of this range had a desirability of 0. This can be described by the following equations:
d1 = 0 for Yi < Ymin
d1 = 1 for Ymin < Yi < Ymax
d1 = 0 for Yi > Ymax
where, d1 is the individual desirability of tensile strength. Yi is the experimental result,
Ymin is the minimum result and Ymax is the maximum result. In addition, the optimum
mucoadhesive film should have high elongation and high percentage of drug retained
on the stomach mucosa. Desirability functions of these responses were calculated using
the following equation:









for Yi < Ytarget
d2 or d3 = 1 for Yi > Ytarget
where d2 is the individual desirability of elongation (%) and d3 is the individual desir-
ability of drug retained (%) on stomach mucosa after 8 h. The values of Ytarget and Ymin
for percentage elongation are 69.85 and 50.31 and the values of Ytarget and Ymin for per-
centage drug released 82.36 and 93.47 while Yi is the experimental result. The overall de-
sirability values were calculated from individual values by using the following equation:
D = (d1 d2 d3)1/3
Physico-chemical characterization. – Mucoadhesive film was characterized for various
aesthetic (appearance, odor, color, flexibility and peelability) and physico-chemical pro-
perties such as moisture content, pH and viscosity of polymeric dispersion, swelling in-
dex, tensile strength, elongation, film thickness, drug concentration uniformity, drug re-
lease and mucoadhesion.
Thickness of each sample was measured using a thickness tester (Model 110, 0.01
mm capacity, Mitutoyo Manufacturing Corporation Ltd., Japan) at five locations (center
and four corners) and mean thickness was calculated.
Viscosity of polymeric dispersion was determined with a Brookfield cone and plate
rheometer (LVDVIII, Brookfield, USA). To study viscosity and pH of the film dispersion,
one unit of formulation was dispersed in 10 mL of distilled water and simulated gastric
fluid (SGF) each. Viscosity of films was measured at 37 ± 1 °C by keeping the spindle
speed 10 rpm and shear rate 10 s–1.
The pH of film dispersion (1.0 ´ 1.0 cm film dissolved in 10 mL each, water and
SGF) was measured with a pH meter (LABINDIA Pvt. Ltd, India) at 30 °C.
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For determination of moisture content, the film sample (1.0 ´ 1.0 cm) was weighed
and kept in a desiccator containing calcium chloride at 40 °C for 24 h. Films were re-
moved from desiccators and reweighed until a constant weight was obtained.
Film swelling study was carried out in simulated gastric fluid. Each film sample with
a surface area 1.0 ´ 1.0 cm was weighed and placed in a preweighed stainless steel bas-
ket with 0.074-mm aperture. Then, the mesh containing film sample was submerged into
15 mL of medium in a glass beaker. Film was removed from the basket at preset time in-
tervals, and reweighed until no further change in weight. Results of the swelling index
of batches GF1 to GF9 are shown in Table II and Fig. 2.
Mechanical properties of films were evaluated using an Instron Universal Testing
Instrument (Model 1121, Instron Limited, UK) equiped with a 100 kg load cell. The film
was cut into narrow strips of 1.0 ´ 1.0 cm. A film strip free from air bubbles or physical
imperfections was placed between two clamps positioned at a distance of 10 mm in the
same plane. During measurement, the lower clamp was fixed and the strip was pulled
by the top clamp at a rate of 100 mm min–1. The force and elongation at the moment of
break were recorded. The results of tensile strength and elongation of batches GF1 to
GF9 are shown in Table II.
Drug concentration. – To ensure uniformity of glipizide distribution in film, the aver-
age drug content in the film was measured. In addition, samples (1.0 ´1.0 cm) were col-
lected from five different locations (centre and four corners) within the film, weighed
and dissolved in 10 mL phosphate buffer (pH 7.4). After 24 h, the solution was filtered
and the filtrate was analyzed spectrophotometrically (Shimadzu UV-1601 UV/Vis dou-
ble beam spectrophotometer, Japan) using the Lambert-Beer’s equation (R2 = 0.9979) for
the drug content at 276 nm. The content of glipizide was calculated using a precon-
structed calibration curve for glipizide (5–50 mg mL–1) in phosphate buffer (pH 7.4).
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Fig. 2. Swelling index of films of var-
ious composition (mean ± SD, n = 3).
Mucoadhesion. – The mucoadhesive property of the film was assessed in a simulated
gastric environment (13) using a texture analyzer equipped with a 2.0 kg load cell
(Model 1121, Instron Limited). Isolated rat stomach mucosa free from supporting tissues
was stored in a deep freezer at –20 °C. For experiments, the stomach intubation tube
(thawed in normal saline) was incised longitudinally and held on the lower platform of
the texture analyzer. The film was applied to the upper probe with the help of a dou-
ble-sided adhesive tap. The stomach mucosa was moistened with SGF. Mucosal mem-
brane was kept in contact with the film for 3 min to allow formation of an adhesive bond.
Upper probe of the texture analyzer was moved at a speed of 0.1 mm s–1. The force re-
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GF1 –1 –1 70.0 7.45 50.31 85.14 0.00
GF2 –1 0 67.5 7.12 54.41 87.52 0.00
GF3 –1 1 65.0 7.02 55.95 93.47 0.00
GF4 0 –1 65.0 10.54 61.68 82.36 0.83
GF5 0 0 62.5 9.75 66.95 83.12 0.90
GF6 0 1 60.0 9.19 69.85 86.61 0.79
GF7 1 –1 60.0 10.33 60.02 84.56 0.67
GF8 1 0 57.5 9.81 61.10 85.14 0.69
GF9 1 1 55.0 9.25 64.15 87.94 0.63
Level
Independent variables Low Medium High
X1 – concentration of hydroxypropyl cellulose (%, m/m) 20 25 30
X2 – concentration of polyethylene glycol 400 (%, m/m) 10 12.5 15

























Fig. 3. Mucoadhesive strength of films
with various polymers-to-plasticizer ra-
tio (mean ± SD, n = 3).
quired to detach the film from the tissue surface was determined as mucoadhesive stren-
gth. Results of the mucoadhesive strength of batches GF1 to GF9 are shown in Table II
and Fig. 3.
Drug release
The drug release study was performed using a USP basket apparatus (Electrolab,
TDT-06T, India) at 37 ± 0.5 °C and at 50 rpm using 900 mL of phosphate buffer (pH 7.4)
as dissolution medium (n = 5) as per the dissolution test prescribed for glipizide exten-
ded release tablets (14). The polymeric film (1.0 ´ 1.0 cm) equivalent to 10 mg of glipi-
zide was used for the test. Five milliliters of sample solution were withdrawn at prede-
termined time intervals, filtered through a 0.45-mm membrane filter, suitably diluted, and
analyzed spectrophotometrically. An equal amount of fresh dissolution medium was re-
placed immediately after withdrawal of the test sample. The average values of Y8 for
batches GF1 to GF9 are given in Table II and the percentage of drug released is shown in
Fig. 4.
Data fitting











where k is the Hixon-Crowell constant [mass/(time)]1/3. In this model, the percentage
drug unreleased vs. cube root of time is linear.
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Fig. 4. In vitro dissolution of glipizide
from mucoadhesive films of batches
GF1-GF9 (mean ± SD, n = 3).
The data was treated with the Korsmeyer-Peppas model (16) to characterize the me-
chanism of drug release:
Mt/M = Kptn
where Mt/M represents the fraction of drug released at time t and Kp is the kinetic con-
stant characterizing the polymeric system and n stands for the diffusion exponent.
The dissolution data was also analyzed using the Weibull equation (15) to determi-
ne the kinetics of drug release from different batches of mucoadhesive films:
m = 1 – exp[–(t–ti)b/a]
where a is the scale parameter which defines the time scale of the process, ti is the loca-
tion parameter which represents the lag period before the actual onset of dissolution
process (in most cases ti = 0) and b is the shape parameter. In this model, the plot of log
of time vs. log(1–m) is linear. The results of F-statistics were used for selection of the
most appropriate model.
In vivo study
In vivo evaluation studies for glipizide mucoadhesive films were performed in nor-
mal healthy Wistar rats weighing 250–300 g each. The Approval of the Institutional Ani-
mal Ethics Committee was obtained before starting the study (Nootan Pharmacy Col-
lege, Gujarat, India). The study was conducted in accordance with standard institutional
guidelines. Two groups of Wistar rats (5 in each group), which were fasted (with water)
at least 12 h before the experiment, were used for the study. Before drug administration,
a blood sample as control was taken from each Wistar rat from behind the eyeball thro-
ugh the angle of ocular cavity using a small capillary tube. The blood glucose level for
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Fig. 5. Reduction in blood glucose le-
vels following oral administration of
glipizide and its mucoadhesive films
in Wistar rats (mean ± SD, n = 5).
control and test samples was determined using the glucose-measuring instrument (Me-
disence Abbott Laboratories, USA). The instrument was self-calibrated, and the samples
were allowed to dry before the results were read to avoid lens contamination. A dose of
800 µg kg–1 of glipizide suspension (freshly prepared in distilled water) and mucoadhe-
sive films of glipizide were administered orally to each group using stomach intubation.
Blood samples were collected at predetermined intervals up to 24 h and the blood glu-
cose level was measured and depicted in Fig. 5.
RESULTS AND DISCUSSION
Drug-excipient compatibility
Drug-excipient compatibility studies were conducted with the objective of selecting
a reasonable composition for mucoadhesive films. Any kind of incompatibility between
glipizide and film-forming polymer affects its performance to a significant extent. Re-
sults of glipizide-excipient compatibility study performed by DSC are shown in Fig. 1.
The DSC curve of pure glipizide exhibits a single endotherm (at 217 °C) corresponding
to the melting point of glipizide. The onset of the melting point was observed at 170.8 °C
and the corresponding heat of fusion was 170.8 J g–1, whereas pure PEG 400 shows a
melting endotherm at 47.8 °C and pure HPC shows a melting endotherm at 74.4 °C. Ther-
mogram of film GF5 shows complete absence of the glipizide melting peak and one en-
dothermic peak at 70.2 °C suggesting that glipizide was completely soluble in the liquid
phase of the polymer and that the crystalline nature of glipizide was lost.
Mechanical properties
Physical characteristics and other mechanical properties of glipizide films contain-
ing HPC and PEG 400 were found acceptable and were therefore selected for further op-
timizations of the formulation. The results of mechanical properties shown in Table II in-
dicate that an increase in HPC concentration resulted in higher tensile strength (TS) and
elongation at break (EB), while increased amount of PEG 400 reflected a decrease in TS
and increase in percentage of EB. An interesting finding was the decrease in TS and in-
crease in percentage of EB of the film as a function of plasticizer by weakening the inter-
molecular interactions between polymer chains. Hence, the optimum level of HPC and
PEG 400 was desired because a high PEG 400 content produced more flexible and softer
films. Glipizide films with HPC were tougher and softer than those without HPC.
Among the tested variables, HPC concentration seems to be the most prominent
factor in determining response values of the film. An interesting observation was im-
proved tensile strength, elongation, Y8 and swelling index as the content of HPC in the
film increased. High concentration of PEG 400 can decrease Y8 and TS values of mu-
coadhesive films and increas the EB value. Desirability function was utilized to find out
the optimum level of HPC and PEG 400 among the nine batches. Desirability function
was calculated for TS, EB and Y8. Batch GF5 showed the highest overall desirability of
0.90. This batch was therefore considered to be optimized and the values of independent
variables of this batch were considered to be optimum values for mucoadhesive films.
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The optimized composition of the film was glipizide (62.5 %, m/m), HPC (25 %, m/m)
and PEG 400 (12.5 %, m/m).
Physico-chemical properties
The newly developed glipizide films are colorless, odorless, flexible, uniform and
possess smooth surface. Films of three different batches of GF5 were found to have simi-
lar aesthetic, mechanical and chemical properties. This suggests that films with desired
properties can be prepared consistently and reproducibly. All the performance parame-
ters of the GF5 film are given in Table III. High viscosity of the polymeric dispersion of
the film was found in SGF compared to water. Viscosity and dispersibility of the formu-
lation in stomach environment after administration governs the spreading and retention
of formulations, which is essential to achieve the desired efficacy. The developed film
was dispersed rapidly in SGF and formed a mucoadhesive layer over stomach mucosa
in order to bring the drug in contact with the target tissue for a sufficient period of time.
The pH of the polymeric film was found to be slightly acidic in SGF. The moisture con-
tent in the optimized film was 7.0 ± 0.2 % (m/m). The small amount of moisture in for-
mulations helped them to remain stable and prevented them from being completely dry
and brittle. The results of scanning electron photomicrographs (not shown) of the film
confirmed that film surface was free from any scratches or transverse striations.
Swelling indices of films with various composition are shown in Fig. 2. Films were
found to be rapidly swollen within 5 min and thereafter slowly reached the plateau. Ma-
ximum swelling was seen with films containing a high content of HPC. As the concen-
tration of PEG 400 in the film increased, the swelling index decreased.
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Table III. Optimum characteristics of the mucoadhesive glipizide film
Parameter Optimum value
Size (cm2) 1.0 ´ 1.0
Mass (mg)a 221.5 ± 4.5
Thickness (mm)a 0.24 ± 0.026
Moisture content (%, m/m)a 6.96 ± 0.22
Tensile strength (N mm–2)b 9.75 ± 0.20











Bioadhesive strength (N)b 0.39 ± 0.01
Drug release after 8 h (%) 83.1
a Mean ± SD, n = 3.
b Mean ± SD, n = 5.
Fig. 3 shows the effect of various polymer/plasticizer ratios on mucoadhesive stren-
gth of the film. The film mucoadhesive strength was improved with increasing HPC con-
centration up to a certain extent, and then it decreased. As the concentration of PEG 400
in the film increased, its mucoadhesive strength was found to decrease. This finding sug-
gests that adhesion will improve with the extent of hydration until an optimum point
where overhydration leads to a decrease in adhesive force due to disentanglement at the
polymer/tissue interface. Amongst nine films, GF5 showed good mucoadhesion in si-
mulated stomach environment.
Retention behavior of films was studied using a simulated dynamic stomach system
that mimiced the physicodynamic conditions of the stomach. The film softened on the
stomach mucosa after absorbing SGF and became a swollen structure, helping it to ad-
here to the stomach mucosa.
The time required for entire removal of the polymeric film from stomach mucosa
varied with the film composition. Film containing a high content of HPC and PEG 400
was removed rapidly from stomach mucosa. As the ratio of HPC to PEG 400 in the film
increased, the residence time of the film increased until an optimum point and then de-
creased. This indicates that retention properties of polymeric films can be controlled by
the varying HPC/PEG 400 ratio. Results of this study clearly indicate that the amount of
HPC and PEG 400 is an integral factor of the residence time of mucoadhesive films.
The percentage of glipizide release as a function of time is shown in Fig. 4. Opti-
mized batch (GF5) exhibited an Y8 of 83.1 % and seems to be a promising candidate for
achieving drug release up to 12 h. The drug release profile of batch GF5 is shown in Fig.
4. The dissolution data of batch GF5 was further analyzed to ascertain the mechanism of
drug release. The mechanism of drug release from the films was found to be diffusion
controlled because plots of cumulative drug release percentage vs. square root of time
were found to be linear ranging from 0.9890–0.9971 for the best batch. The release profile
was fitted to the Weibull equation (15); F-value was found to be 8.14 and was found to
be 0.9762. For the release profile fitted to the Korsmeyer-Peppas equation (16), F-value
was found to be 24.66 and R2 0.9845, and after fitting to Hixon-Crowell equation (15),
F-value was found to be 12.52 and R2 0.9789. The results of F-statistics were used for the
selection of the most appropriate model; it was thus concluded that the release profile
fitted best to Weibull equation.
In vivo study
In vivo efficiency of the optimized batch GF5 was tested on healthy normal Wistar
rats by measuring the hypoglycemic effect produced after oral administration. The drug
was administered at a dose equivalent to 800 mg kg–1 pure glipizide, and glipizide mu-
coadhesive films were used. Pure glipizide was administered in a suspension at the sa-
me dose. When pure glipizide suspension was administered, a rapid reduction in blood
glucose level was observed; maximum reduction of 48 % was observed within 2 h after
oral administration. Blood glucose levels recovered rapidly to the original level within 8 h
(Fig. 5). In the case of glipizide mucoadhesive films, the reduction in blood glucose lev-
els was slow and reached maximum reduction within 4 h after oral administration. This
reduction in blood glucose levels ( 25 %) was sustained over a longer period of time (12 h).
Kahn et al. (17) have suggested that a 25 % reduction in blood glucose levels is consi-
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dered to be a potential hypoglycemic effect. Potential hypoglycemic effect (25 %) was
maintained only from 0.5 to 5 h after oral administration of glipizide, whereas in the
case of mucoadhesive glipizide films, potential hypoglycemic effect (25 %) was main-
tained for a period of 2 to 12 h. Sustained hypoglycemic effect observed over a longer
period of time in the case of mucoadhesive films was due to the slow release and ab-
sorption of glipizide over longer periods of time. Glipizide sustained release formula-
tion is significantly more effective than the immediate release formulation of glipizide in
reducing fasting plasma glucose levels and side effects (18).
CONCLUSION
The overall results obtained during this investigation suggest that glipizide muco-
adhesive films possessed desirable aesthetic, pharmaceutical and biological properties.
The in vivo study demonstrated potential hypoglycemic activity of the mucoadhesive film
with glipizide.
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S A @ E T A K
Priprava i evaluacija mukoadhezivnih filmova glipizida
GANESH RAJPUT, FALGUNI MAJMUDAR i JAYVADAN PATEL
Glipizid se prete`no apsorbira u proksimalnom dijelu gastrointestinalnog trakta. Cilj
rada je priprava i evaluacija mukoadhezivnih filmova s kojima bi se produljilo zadr`a-
vanje lijeka u predjelu apsorpcije. Pripravljeni su mukoadhezivni filmovi glipizida koji
se produljeno zadr`avaju u `elucu. Polimerni filmovi sadr`avali su razli~ite koli~ine hi-
droksipropil celuloze i polietilen glikola 400 (PEG 400). Evaluirana su sljede}a svojstva
mukoadhezivnih filmova: ~vrsto}a, postotak elongacije, indeks bubrenja, sadr`aj vlage,
pH i viskoznost polimerne disperzije, debljina filma, koncentracija lijeka, jednolikost i
mukoadhezivnost u simuliranom `elu~anom soku. Na dinami~kom modelu `eluca od-
re|ivan je i postotak lijeka koji se zadr`ava u sluznici `eluca u ovisnosti o vremenu. Po-
ve}anjem koncentracije hidroksipropil celuloze pove}avaju se ~vrsto}a i elongacija, dok
se pove}anje koncentracije PEG 400 reflektira na smanjenje ~vrsto}e i pove}anje elonga-
cije kod loma. Omjer glipizid/hidroksipropil celuloza/PEG 400 (2,5:1:0,5) (GF5) bio je
optimalan za pripravu mukoadhezivnih formulacija, s dobrom kalavo{}u, relativno vi-
sokim indeksom bubrenja, umjerenom ~vrsto}om te zadr`avanjem u sluznici `eluca {ta-
kora do 8 h. U in vivo testiranjima mukoadhesivni filmovi s glipizidom pokazali su po-
tencijalni hipoglikemijski u~inak.
Klju~ne rije~i: glipizid, mukoadhezivni film, faktorijalno dizajniranje, funkcija po`eljnosti, hipogli-
kemijski u~inak
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